2025.02.23本文字数:605,阅读时长大约2分钟导读:辉瑞终止B型血友病基因疗法Beqvez的全球开发与商业化,该疗法去年4月获FDA批准,定价350万美元。辉瑞称患者和医生兴趣有限,自获批以来无人使用。此前,辉瑞还终止了与Sangamo合作的A型血友病基因疗法,并撤回镰状细胞贫血疗法Oxbryta。此外,罗氏、bluebird bio等也纷纷砍掉或放弃基因治疗项目,基因疗法商业化面临严峻...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.